TNFSF10 and colorectal carcinoma: The first study that surveyed the application of genetically modified MSCs in CRC therapy was performed by Luetzkendorf et al. in 2009; they assessed the usage of BMSCs in the delivery of TNF-related apoptosis-inducing ligand (TRAIL) as a proapoptotic factor in CRC therapy (77).